CAS 869884-78-6
:Radezolid
Description:
Radezolid is a synthetic antibiotic belonging to the oxazolidinone class, primarily developed for the treatment of Gram-positive bacterial infections, including those caused by resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). Its mechanism of action involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing the formation of functional ribosomes. Radezolid exhibits a broad spectrum of activity against various pathogens, making it a valuable option in the fight against antibiotic resistance. The compound is characterized by its stability in the presence of certain enzymes that typically degrade other antibiotics, which enhances its efficacy. Additionally, Radezolid has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, which are crucial for determining appropriate dosing regimens. As with many antibiotics, potential side effects may include gastrointestinal disturbances and the risk of developing resistance if not used judiciously. Overall, Radezolid represents a promising advancement in antibiotic therapy, particularly for challenging infections.
Formula:C22H23FN6O3
InChI:InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)/t19-/m0/s1
InChI key:InChIKey=BTTNOGHPGJANSW-IBGZPJMESA-N
SMILES:O=C1N(C2=CC(F)=C(C=C2)C3=CC=C(CNCC4=CN=NN4)C=C3)C[C@H](CNC(C)=O)O1
Synonyms:- Acetamide, N-[[(5S)-3-[2-fluoro-4′-[[(1H-1,2,3-triazol-4-ylmethyl)amino]methyl][1,1′-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-
- Acetamide, N-[[(5S)-3-[2-fluoro-4′-[[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1′-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-
- N-[[(5S)-3-[2-Fluoro-4'-[[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide
- Radezolid
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
